On the January 9th, several Taiwan pharmaceutical companies went to the 2017 J.P. Morgan 35th annual healthcare conference to report on company profile and progress of its products, the members included ScinoPharm, Microbio group, TLC and other 15 companies, showing that Taiwan’s new drug companies gradually cut a striking figure in the international arena. Biotech stocks were not dragged down as expected, new drug stocks were only slightly lower and general pharmaceutical stocks still rised, indicating that the biotechnology industry was gradually decoupled from the case of OBI PHARMA, and not affected by this negative impact.

J.P. Morgan annual healthcare conference is the most important event of global biotechnology pharmaceutical industry,the conference will focus on the current health care policy, current status of biotechnology and pharmaceutical industry, new technology and future trends. It is reported that this event in the industry’s authority has become an essential conference for investors around the world, biotech pharmaceutical company executives, fund managers, analysts and entrepreneurs.

Microbio group has been invited to participate in J.P. Morgan annual healthcare conference and would make a project report on three subsidiaries, including Microbio, Oneness Biotech and Fountain Biopharma. Microbio has obtained 2 new drug licenses in Taiwan, while the diabetic wound healing drugs ON- 101 of Oneness Biotech was also about to apply new drug license and executed the international phase III clinical trials; Fountain Biopharma’s key antibody anti-CεmX (FB825) has also started phase II human clinical trial.